Trending Stock News

Hologic (HOLX) Holding Maintained by Waterstone Capital Management Lp; Coe Capital Management Stake in Abbvie (ABBV) Has Cut by $308,160

Hologic, Inc. (NASDAQ:HOLX) Logo

Mark Coe decreased its stake in Abbvie Inc (ABBV) by 10.94% based on its latest 2017Q4 regulatory filing with the SEC. Coe Capital Management Llc sold 3,210 shares as the company’s stock declined 6.31% with the market. The hedge fund run by Mark Coe held 26,137 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $2.53 million, down from 29,347 at the end of the previous reported quarter. Coe Capital Management Llc who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $162.89 billion market cap company. The stock decreased 2.79% or $2.95 during the last trading session, reaching $102.65. About 7.39 million shares traded or 1.24% up from the average. AbbVie Inc. (NYSE:ABBV) has risen 39.20% since May 24, 2017 and is uptrending. It has outperformed by 27.65% the S&P500.

Shawn Bergerson increased its stake in Hologic Inc (HOLX) by 14.21% based on its latest 2017Q4 regulatory filing with the SEC. Waterstone Capital Management Lp bought 55,600 shares as the company’s stock declined 13.23% with the market. The hedge fund run by Shawn Bergerson held 446,800 shares of the health care company at the end of 2017Q4, valued at $19.10 million, up from 391,200 at the end of the previous reported quarter. Waterstone Capital Management Lp who had been investing in Hologic Inc for a number of months, seems to be bullish on the $10.62 billion market cap company. The stock increased 0.17% or $0.06 during the last trading session, reaching $38.88. About 621,415 shares traded. Hologic, Inc. (NASDAQ:HOLX) has declined 11.91% since May 24, 2017 and is downtrending. It has underperformed by 23.46% the S&P500.

Investors sentiment decreased to 0.8 in 2017 Q4. Its down 0.05, from 0.85 in 2017Q3. It fall, as 42 investors sold ABBV shares while 695 reduced holdings. 139 funds opened positions while 448 raised stakes. 1.06 billion shares or 0.35% more from 1.06 billion shares in 2017Q3 were reported. Amer Assets Investment Mgmt Lc holds 0.85% or 46,000 shares in its portfolio. Shamrock Asset Management Limited Co stated it has 2,878 shares. Dorsey And Whitney Tru Comm Ltd Liability Corporation stated it has 0.34% of its portfolio in AbbVie Inc. (NYSE:ABBV). Zeke Capital Advisors Ltd Liability Corporation stated it has 0.31% in AbbVie Inc. (NYSE:ABBV). Northeast Mngmt stated it has 10,033 shares or 0.08% of all its holdings. Envestnet Asset Management Inc, a Illinois-based fund reported 290,903 shares. Taylor Frigon Capital Management Limited Liability Corp reported 14,040 shares. Credit Agricole S A owns 64,697 shares or 0.42% of their US portfolio. Hgk Asset reported 7,835 shares. Chilton Cap Ltd Liability Com has 0.09% invested in AbbVie Inc. (NYSE:ABBV). Iowa National Bank & Trust accumulated 65,546 shares. Sit Investment Associate Incorporated holds 426,690 shares. Kames Cap Public Ltd Com invested in 306,833 shares. Evermay Wealth Mgmt Ltd Liability Company reported 11,991 shares. Field Main National Bank accumulated 0.89% or 9,600 shares.

Among 23 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 11 Hold. Therefore 43% are positive. Abbvie Inc had 92 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, January 30. The company was maintained on Monday, February 26 by Jefferies. The stock has “Buy” rating by Piper Jaffray on Thursday, September 28. The rating was initiated by Raymond James with “Outperform” on Friday, September 2. Credit Suisse maintained the shares of ABBV in report on Wednesday, June 7 with “Hold” rating. JP Morgan downgraded AbbVie Inc. (NYSE:ABBV) on Thursday, September 8 to “Neutral” rating. The stock has “Buy” rating by Jefferies on Friday, July 14. The stock of AbbVie Inc. (NYSE:ABBV) has “Underperform” rating given on Tuesday, January 30 by BMO Capital Markets. Jefferies maintained AbbVie Inc. (NYSE:ABBV) on Friday, March 23 with “Buy” rating. The firm has “Buy” rating by Jefferies given on Monday, June 26.

Since December 14, 2017, it had 0 insider purchases, and 11 selling transactions for $47.70 million activity. On Wednesday, February 28 Michael Robert A. sold $512,853 worth of AbbVie Inc. (NYSE:ABBV) or 4,294 shares. Shares for $8.31 million were sold by CHASE WILLIAM J on Wednesday, February 28. 8,280 AbbVie Inc. (NYSE:ABBV) shares with value of $976,084 were sold by GONZALEZ RICHARD A. $311,684 worth of AbbVie Inc. (NYSE:ABBV) shares were sold by SEVERINO MICHAEL. $8.57M worth of AbbVie Inc. (NYSE:ABBV) shares were sold by RICHMOND TIMOTHY J.. 145,510 AbbVie Inc. (NYSE:ABBV) shares with value of $14.07 million were sold by Schumacher Laura J.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on July, 27. They expect $1.97 EPS, up 38.73% or $0.55 from last year’s $1.42 per share. ABBV’s profit will be $3.13B for 13.03 P/E if the $1.97 EPS becomes a reality. After $1.87 actual EPS reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 5.35% EPS growth.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Streetinsider.com which released: “AbbVie (ABBV) Reports IMBRUVICA (ibrutinib) Plus GAZYVA (obinutuzumab) Phase 3 iLLUMINATE (PCYC-1130 …” on May 24, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on May 24, 2018, Seekingalpha.com published: “AbbVie Is Still A One-Trick Pony” on April 26, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Seekingalpha.com and their article: “AbbVie: Can Mylan Pull Off A Humira Biosimilar?” published on May 01, 2018 as well as Streetinsider.com‘s news article titled: “Goldman Sachs Downgrades Abbvie (ABBV) to Buy” with publication date: May 24, 2018.

Waterstone Capital Management Lp, which manages about $2.46 billion and $137.55 million US Long portfolio, decreased its stake in Kroger Co (NYSE:KR) by 142,500 shares to 82,500 shares, valued at $2.27M in 2017Q4, according to the filing.

Since February 13, 2018, it had 3 insider buys, and 2 sales for $195,159 activity. Another trade for 5,200 shares valued at $199,826 was made by Wendell Amy McBride on Wednesday, March 14. The insider Nawana Namal bought 6,600 shares worth $250,023. On Wednesday, March 14 the insider Dockendorff Charles J bought $504,400. $487,840 worth of Hologic, Inc. (NASDAQ:HOLX) was sold by Oberton Karleen Marie.

Another recent and important Hologic, Inc. (NASDAQ:HOLX) news was published by Benzinga.com which published an article titled: “Leerink Downgrades Hologic After ‘Lower Quality’ Q2 Revenue Beat” on May 03, 2018.

Investors sentiment decreased to 0.74 in Q4 2017. Its down 0.14, from 0.88 in 2017Q3. It turned negative, as 57 investors sold HOLX shares while 165 reduced holdings. 70 funds opened positions while 94 raised stakes. 264.36 million shares or 0.45% less from 265.54 million shares in 2017Q3 were reported. 444,100 were reported by Eaton Vance. Geode Mgmt Limited Liability stated it has 0.04% in Hologic, Inc. (NASDAQ:HOLX). North Star Asset Mgmt Inc holds 0.85% or 222,423 shares in its portfolio. Parametric Associates holds 0.02% of its portfolio in Hologic, Inc. (NASDAQ:HOLX) for 449,295 shares. 870,442 were accumulated by Td Asset Mgmt. Paloma Prtnrs Management Company reported 0.02% stake. Hanson Doremus Inv Management has 400 shares. Barclays Public Limited Co invested in 0.01% or 359,236 shares. Hartford Inv Management holds 56,856 shares. Apg Asset Mgmt Nv holds 0.01% or 134,451 shares in its portfolio. Gateway Advisers Ltd Liability Com reported 0.19% stake. Raymond James & Assocs owns 74,354 shares. 156,850 are owned by Sei Invests. Mason Street Advsr Llc invested 0.04% of its portfolio in Hologic, Inc. (NASDAQ:HOLX). Moreover, Northern Trust has 0.04% invested in Hologic, Inc. (NASDAQ:HOLX) for 3.58M shares.

Among 18 analysts covering Hologic (NASDAQ:HOLX), 12 have Buy rating, 0 Sell and 6 Hold. Therefore 67% are positive. Hologic had 63 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, February 9 by Cowen & Co. The firm has “Buy” rating given on Wednesday, January 3 by Canaccord Genuity. The company was maintained on Tuesday, January 9 by Needham. The stock of Hologic, Inc. (NASDAQ:HOLX) has “Overweight” rating given on Thursday, August 3 by Barclays Capital. Needham maintained Hologic, Inc. (NASDAQ:HOLX) rating on Wednesday, August 23. Needham has “Buy” rating and $50.0 target. The stock has “Neutral” rating by Bank of America on Wednesday, February 15. The rating was upgraded by Cowen & Co to “Outperform” on Monday, December 11. The firm has “Hold” rating given on Thursday, May 3 by Leerink Swann. Cowen & Co maintained the shares of HOLX in report on Thursday, August 3 with “Hold” rating. The rating was upgraded by Bank of America to “Buy” on Thursday, January 4.

Hologic, Inc. (NASDAQ:HOLX) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *